Emerging enforcement trends include FDA focus on documentation and identity testing, and increased scrutiny of online claims < Back Compliance in the Digital Age: Navigating Enforcement, Marketing Risks, and the Rise of AI | State of the Supplement Industry Asa Waldstein Guest Article Emerging enforcement trends include FDA focus on documentation and identity testing, and increased scrutiny of online claims Although the pace of FDA warning letters to dietary supplement companies appears to have slowed over the past 12 months, several important enforcement themes continue. GMP compliance remains a central focus, particularly regarding incomplete identity and finished product composition testing. The FDA’s long-standing mantra still applies: If it’s not written down, it didn’t happen. Read More Previous Next

NAD challenge cases explored < Back Fruit Snack Wars NAD challenge cases explored The fruit snack wars are on! A few months ago, I wrote about General Mills challenging television commercials by Welch's Fruit Snacks (PIM's). In the commercials, chef Gordon Ramsay throws away "Fruit Flavored Snacks" by tossing them out of a window. That post includes information on "ash canning," an advertising term that describes the practice of portraying competing products as so inferior that they might as well be discarded like ashes. Read that post here . In this case, Welch's Fruit Snacks (PIM's), who was previously on the defense, challenged several claims made by the Mott's brand of General Mills. This shows that bringing NAD cases can have the added ramification of reciprocal action. 👉From NAD. Although these seem minor, they will likely lead to plaintiff lawsuits and demand letters, which are the biggest"impacts" of NAD decisions. "NAD found that General Mills failed to support these implied claims through challenged social media posts and by reviews reposted by General Mills, including: 🔹"These are great. Way [sic] to get my kids to eat fruits and vegetables. They have [had] a package each night after dinner for years and years." 🔹"My kids love eating these and I love the fact that it's made with real fruits and vegetables and no artificial colors. It helps with trying to show them how to eat mindfully and healthy." You may be asking yourself what the big deal is with fruit snacks. I looked this up. Apparently, this is a $4 billion industry in the US. Also, as a complete aside, every time I hear the name Mott's, I think about this 1987 commercial . Read the NAD case here . DATE ORIGINALLY POSTED: 12/4/24 Disclaimer: The educational information provided here is for informational purposes only. Contact an attorney for specific legal advice. Rule #1 in compliance is to ensure marketing is truthful and not misleading. Previous Next Get Warning Letter Wednesday in your Inbox Sign-Up Now!

Asa Waldstein quoted < Back FDA, FTC slap CBD industry with seven warning letters related to COVID claims Hemp Industry Daily Relevant Article Asa Waldstein quoted Read More Previous Next

Use caution copy & pasting “ingredient benefits” onto commercial website < Back Learning targets: Children, risky words, intranasal, ingredient benefits Use caution copy & pasting “ingredient benefits” onto commercial website #WarningLetterWednesday is a cautionary tale for companies new to the space that are looking to market products. This company looks like a groovy crystal shop that started making topical products and products delivered to the eyes and nose. So what can we learn? 🔷Of course, there are high risks words referenced in the warning letter, Notably, the use of viruses, cancer, and so many more! 🔷Products delivered through the nose (intranasal) or as an eye drop are drugs and have a justifiable higher level of scrutiny. 🔷Products marketed for use by children are high-risk. 🔷This warning letter is a good teaching tool. Copying and pasting a product's "therapeutic uses" from a textbook or website is a great way to get into trouble. This appears to be the case here. ➡️From warning letter Colloidal silver is used to treat infections due to yeast; bacteria (tuberculosis, Lyme disease, bubonic plague, pneumonia, leprosy, gonorrhea, syphilis, scarlet fever, stomach ulcers, cholera); parasites (ringworm, malaria); and viruses (HIV/AIDS, pneumonia, herpes, shingles, warts). 🔷I understand these are obvious high-risk claims, but in some ways, this could have happened to any entrepreneur that doesn't understand the rules of marketing products. I have seen this happen several times with practitioners, herbalists, and even doctors that "cross the line" into marketing claims by using common therapeutic language such as anti-inflammatory and even "clears heat and resolves toxins." We talk about this here . ➡️From warning letter .... to heal skin irritations and scarring. 🔷Interestingly, there are a couple of references to helping skin irritations and scarring. I do not consider these to be high risk. They are likely a "pig pile" or a common secondary claim in warning letters. What are your thoughts on the risk level here? Read warning letter here . 👉In closing, I think the FDA would have left this company alone if there were not talking about viruses, selling products that go into the nose and eyes, are marketed as safe for children, and had just too many disease words to be avoided. I started a LinkedIn group just for warning letter discussion. Join here . Disclaimer: The educational information provided here is for informational purposes only. Contact an attorney for specific legal advice. Rule #1 in compliance is to ensure marketing is truthful and not misleading. Previous Next Get Warning Letter Wednesday in your Inbox Sign-Up Now!

< Back Panel Discussion, Workshop Monday Oct 28, 2024 Education session – Ingredient claims and legal flames: An interactive workshop to dodge regulatory heat SupplySide West Las Vegas, NV Noncompliant dietary supplement ingredient claims can be one of the reasons the Food and Drug Administration comes knocking. In this education session and interactive workshop, experts will dissect the U.S. regulations, laws and guidance that govern ingredient claims, as well as applicable court cases. The audience will apply these learnings in live polling, and then discuss and debate the results. If you’re a professional in marketing, science or regulatory affairs, don’t miss this practical, hands-on workshop. Katie Bond of Keller and Heckman LLP Stephanie-Anne Girard of SGS Nutrasource Corey Hilmas of KGK Science Josh Long of SupplySide Supplement Journal Theodora ("Teddy") McCormick of Epstein Becker & Green, P.C. Asa Waldstein of Supplement Advisory Group and Apex Compliance View Event Schedule Previous Next

Dietary supplement consultant Asa Waldstein reviews regulatory trends over the last quarter in his FDA warning letter roundup column. < Back Q1 2024 warning letter roundup with Asa Waldstein Asa Waldstein Guest Article Dietary supplement consultant Asa Waldstein reviews regulatory trends over the last quarter in his FDA warning letter roundup column. Read More Previous Next

The head of FDA's Office of Dietary Supplement Programs and a dozen others offered their perspective on the recent DSHEA at 30 Summit in Salt Lake City. < Back FDA, industry experts reflect on DSHEA at 30 Summit Josh Long Interview The head of FDA's Office of Dietary Supplement Programs and a dozen others offered their perspective on the recent DSHEA at 30 Summit in Salt Lake City. Asa Waldstein, principal, Supplement Advisory Group: “The DSHEA Summit was a well-structured and moderated event that provided a wonderful opportunity for stakeholders in the natural wellness space to come together, appreciate and contextualize the origins and initial purposes of DSHEA, align concerning the current status of regulation in the space, and exchange ideas about what adjustments or improvements are needed. We need to use this opportunity to move forward in achieving our shared goals together. DSHEA is a remarkable statute that accomplished both expected and unexpected results. We should work to improve upon DSHEA and not simply abandon it or rush into new legislation that betrays its underlying principle of empowering consumers to make informed decisions about managing their own health and wellness.” Read More Previous Next

FDA will test suspicious products for drugs < Back Male Enhancement Products Found with Drug-Spiked Ingredients FDA will test suspicious products for drugs FDA has issued two drug-spiked product warning letters this year! This is the type of action I appreciate seeing the FDA do, as this small number of bad actors in the market gives the dietary supplement industry a bad name. Sign up for my weekly Warning Letter Wednesday post. FDA tested these products and found them to contain active ingredients in Viagra and Cialis. The company's product claims about erectile dysfunction likely triggered FDA to test these products, and several ED claims are cited in the warning letters. Erectile dysfunction may be considered a disease claim and should be avoided. But how about libido, sexual performance, and aphrodisiac claims? Do you think these types of statements are structure-function statements? In my opinion, libido-type claims attract FDA attention and require additional testing on Amazon, but they, if substantiated, are likely in the lower-risk category as long as companies are testing to ensure there are no unintentional drug-spiked ingredients. I rarely tell jokes on Warning Letter Wednesday, but I can’t help this one. “Why did the lizard go to the doctor?... He had reptile dysfunction.” In this warning letter , the timeline is perplexing. FDA inspected the manufacturer and conducted a website review in June 2022. FDA tested a product and found the presence of sildenafil which is the active ingredient in Viagra. Then in August 2022, the company issued a recall for one lot of the seven-count product. Two months later FDA issued a public notification warning consumers about these products, and now in January 2023, the company was issued a warning letter. What can we do to help get these drug-spiked products off the markets sooner? This warning letter from yesterday also has an even more bizarre timeline. FDA reviewed the website and potentially tested products in May 2022. In July 2022 FDA issued a public notification warning consumers about the presence of tadalafil in these products. Then, just last month FDA re-reviewed their website and found the company apparently still selling these products, which led to this warning letter. Again I ask, ‘What can we do to help get these drug-spiked products off the markets sooner?’ Disclaimer: The educational information provided here is for informational purposes only. Contact an attorney for specific legal advice. Rule #1 in compliance is to ensure marketing is truthful and not misleading. Previous Next Get Warning Letter Wednesday in your Inbox Sign-Up Now!